Results 11 to 20 of about 1,171 (123)

Donor-Cell Origin High-Risk Myelodysplastic Syndrome Synchronous with an Intracranial Meningioma-Like Tumor, 8 Years after Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia

Case Reports in Medicine, 2017
Secondary neoplasias are well known consequences of radiotherapy or chemotherapy for a primary cancer. In this report, we describe two rare secondary neoplasias occurring in the same patient: a meningioma-like intracranial tumor and high-risk ...
G. Brás, C. Pinho-Vaz, A. Campos
doaj   +2 more sources

Tacrolimus Concentration/Dose Ratio in Hematopoietic Cell Transplantation Recipients: An Exploratory Study of Metabolizer Phenotyping and Clinical Outcomes. [PDF]

Clin Transl Sci
ABSTRACT Tacrolimus pharmacokinetics shows wide interindividual variability after allogeneic hematopoietic cell transplantation (HCT), potentially influencing both effectiveness and toxicity. The concentration‐to‐dose (C/D) ratio has been proposed as a simple surrogate marker of tacrolimus metabolism, enabling patient stratification into fast or slow ...
da Costa-Junior LC, Tavares RCBDS, Izu M, Maradei SC, Moreira MCR, Nogueira MC, Lerner D, de Souza Fernandez T, Santos PCJL.   +8 more
europepmc   +2 more sources

Haploidentical Stem Cell Transplantation With Dual Source of Cells and Post-Transplant Cyclophosphamide. [PDF]

Cancer Med
ABSTRACT Background Dual sources of cells (DSC) with peripheral blood stem cell apheresis (PBSC) and surgical bone marrow (BM) for haploidentical hematopoietic cell transplantation (Hid‐HCT) are used in China and some Asian countries. The experience of the Baltimore group for haploidentical transplant with post‐transplant cyclophosphamide (PT‐Cy) and ...
Fonseca-Hial AMR, Parisio K, de Oliveira JSR.   +2 more
europepmc   +2 more sources

Health‐related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real‐world Study by the GIMEMA

HemaSphere, Volume 7, Issue 9, September 2023., 2023
Health‐related quality of life (HRQoL) is an important goal of therapy for patients with myelodysplastic syndromes (MDS); however, little is known about HRQoL of these patients at clinical presentation. We report HRQoL profile of newly diagnosed patients with MDS across both the the International Prognostic Scoring System (IPSS) and IPSS‐Revised (IPSS ...
Fabio Efficace, Wael Al Essa, Uwe Platzbecker, Pasquale Niscola, Giuseppe A. Palumbo, Giovanni Caocci, Francesco Cottone, Massimo Breccia, Mario Luppi, Reinhard Stauder, Alessandra Ricco, Duska Petranovic, Frederic Baron, Maria Teresa Voso, Luana Fianchi, Chiara Frairia, Isabella Capodanno, Chiara Sarlo, Marilena Fedele, Roberto Massimo Lemoli, Rosangela Invernizzi, Daniele Vallisa, Nicola Di Renzo, Claudio Fozza, Maribel Doro, Johannes M. Giesinger, Marco Vignetti   +26 more
wiley   +1 more source

Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms

HemaSphere, Volume 5, Issue 7, July 2021., 2021
Mutations in the calreticulin (CALR) gene are seen in about 30% of essential thrombocythemia and primary myelofibrosis patients. To address the contribution of the human CALR mutants to the pathogenesis of myeloproliferative neoplasms (MPNs) in an endogenous context, we modeled the CALRdel52 and CALRins5 mutants by induced pluripotent stem cell (iPSC ...
Lise Secardin, Cintia Gomez Limia, Suzana da Silva‐Benedito, Larissa Lordier, Mira El‐Khoury, Caroline Marty, Jean‐Christophe Ianotto, Hana Raslova, Stefan N. Constantinescu, Martín Hernán Bonamino, William Vainchenker, Barbara Monte‐Mor, Antonio Di Stefano, Isabelle Plo   +13 more
wiley   +1 more source

Relato de experiência: abordagem multidisciplinar na anemia aplástica – desenvolvimento de um modelo de assistência ambulatorial

HU Revista, 2021
Introdução: A anemia aplástica é uma doença hematológica rara, que cursa com alta morbidade e mortalidade. O tratamento é definido pela idade do paciente, classificação da gravidade, comorbidades existentes e disponibilidade de um doador compatível para ...
Adriana Aparecida Ferreira, Camila Mariana de Araújo Silva Vieira, Débora Wagner, Flávio Rodrigues Reis   +3 more
doaj   +1 more source

Experiência do Centro Nacional de Transplante de Medula Óssea (CEMO) com uso de Cateteres tipo Hickman-Broviac

Revista Brasileira de Cancerologia, 2023
 Quarenta e sete pacientes foram admitidos no Centro Nacional de Transplante de Medula Óssea - CEMO - do Rio de Janeiro, tendo sido introduzidos 57 cateteres de Hickman-Broviac.
Eduardo D. Velasco, Luis Fernando da Silva Bouzas, Daniel Tabak   +2 more
doaj   +1 more source

UM MODELO DE EVOLUÇÃO PARA SÍNDROME MIELODISPLÁSICA PEDIÁTRICA: SOB UM OLHAR CITOGENÉTICO E EPIGENÉTICO

Hematology, Transfusion and Cell Therapy, 2021
Objetivos: A síndrome mielodisplásica pediátrica (SMD-p) é rara, sua etiopatologia é complexa e ainda não se sabe a causa de seu surgimento. Embora avanços rápidos tenham sido feitos na SMD no adulto, a genética e epigenética da SMD-p ainda são pouco ...
VL Lovatel, EF Rodrigues, CS Fernandez, RC Tavares, APS Bueno, AS Fonte, ES Costa, E Abdelhay, SCS Lima, TS Fernandez   +9 more
doaj   +1 more source

Transplante de Medula Óssea

Revista Brasileira de Cancerologia, 2023
Artigo de opinião, de Mary Evelyn Dantas Flowers do Instituto Nacional de Câncer (INCA) sobre a função, a finalidade e os resultados obtidos com o transplante de medula óssea (TMO).
Mary Evelyn Dantas Flowers
doaj   +1 more source

APLASIA DE MEDULA ÓSSEA NA INFÂNCIA. RESULTADOS TERAPÊUTICOS NO CENTRO INFANTIL BOLDRINI

Hematology, Transfusion and Cell Therapy, 2023
Objetivos: Avaliação dos resultados terapêuticos em pacientes portadores de aplasia de medula óssea grave e muito grave, não constitucional, no período de 2018 a 2023 no Centro Infantil Boldrini segundo o tipo de tratamento recebido.
C Omae, MPA Verissimo, MCD Piazza, JC Yajima, AC Azevedo, L Prandi, MBR Amaral, A Salgado, TN Ferreira, SR Brandalise   +9 more
doaj   +1 more source